These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 9815793)

  • 1. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
    Schirrmacher V; Haas C; Bonifer R; Ertel C
    Clin Cancer Res; 1997 Jul; 3(7):1135-48. PubMed ID: 9815793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response.
    Von Hoegen P; Weber E; Schirrmacher V
    Eur J Immunol; 1988 Aug; 18(8):1159-66. PubMed ID: 2970967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
    Haas C; Strauss G; Moldenhauer G; Iorio RM; Schirrmacher V
    Clin Cancer Res; 1998 Mar; 4(3):721-30. PubMed ID: 9533542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral hemagglutinin augments peptide-specific cytotoxic T cell responses.
    Ertel C; Millar NS; Emmerson PT; Schirrmacher V; von Hoegen P
    Eur J Immunol; 1993 Oct; 23(10):2592-6. PubMed ID: 8405059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus.
    Fournier P; Zeng J; Von Der Lieth CW; Washburn B; Ahlert T; Schirrmacher V
    Int J Oncol; 2004 Mar; 24(3):623-34. PubMed ID: 14767547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
    Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
    Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
    Aigner M; Janke M; Lulei M; Beckhove P; Fournier P; Schirrmacher V
    Int J Oncol; 2008 Apr; 32(4):777-89. PubMed ID: 18360705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma vaccine based on the vector of membrane fusogenic liposomes.
    Qiang L; Yi J; Fu-De C
    Pharmazie; 2004 Apr; 59(4):263-7. PubMed ID: 15125569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.
    Sturmhoefel K; Lee K; Gray GS; Thomas J; Zollner R; O'Toole M; Swiniarski H; Dorner A; Wolf SF
    Cancer Res; 1999 Oct; 59(19):4964-72. PubMed ID: 10519410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
    Haas C; Herold-Mende C; Gerhards R; Schirrmacher V
    Cancer Gene Ther; 1999; 6(3):254-62. PubMed ID: 10359211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
    Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
    Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters.
    Zatloukal K; Schneeberger A; Berger M; Schmidt W; Koszik F; Kutil R; Cotten M; Wagner E; Buschle M; Maass G
    J Immunol; 1995 Apr; 154(7):3406-19. PubMed ID: 7897222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antitumor research on mouse melanoma with combined application of Newcastle disease virus and its HN gene].
    Mi ZQ; Jin NY; Sun YC; Li X; Lian H; Li J; Guan GF
    Ai Zheng; 2004 Aug; 23(8):910-3. PubMed ID: 15301713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response.
    Zhao L; Mei Y; Sun Q; Guo L; Wu Y; Yu X; Hu B; Liu X; Liu H
    J Immunol; 2014 Jul; 193(2):735-45. PubMed ID: 24943214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV).
    Plaksin D; Porgador A; Vadai E; Feldman M; Schirrmacher V; Eisenbach L
    Int J Cancer; 1994 Dec; 59(6):796-801. PubMed ID: 7989121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
    Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
    Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.